GlassScriptPhysician profile
Timothy Hart
NPI 1174668420
$9,634.37
in general payments reported to CMS, 2019-2025
37 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $1,107 · 2021: $1,521 · 2022: $1,458 · 2023: $1,948 · 2024: $1,471 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,227.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,646.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,396.73 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $911.14 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $675.08 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $644.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $529.76 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $454.73 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.12 | 2019-2025 | Xifaxan |
| Allergan, INC. | $376.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $372.30 | 2019-2023 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $285.98 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $277.72 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novartis Pharmaceuticals Corporation | $259.99 | 2019-2024 | |
| Esperion Therapeutics, INC. | $239.32 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $214.19 | 2019-2023 | Seglentis, Livalo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $163.33 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.38 | 2022-2025 | Jardiance |
| Abbott Laboratories | $88.49 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $86.91 | 2022 | |
| Amgen INC. | $63.12 | 2019-2024 | Prolia, Evenity |
| Almatica Pharma LLC | $57.36 | 2021-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Lundbeck LLC | $44.84 | 2023 | Rexulti |
| Eisai INC. | $39.35 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.11 | 2019-2021 | |
| Alkermes, INC. | $37.61 | 2023 | Aristada, Lybalvi |
| Mylan Specialty L.P. | $36.06 | 2022-2023 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $35.70 | 2021 | |
| Glaxosmithkline, LLC. | $32.89 | 2023-2025 | Shingrix |
| Shire North American Group INC | $28.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.98 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.80 | 2025 | Unithroid |
| Abiomed | $16.03 | 2025 | |
| Sunovion Pharmaceuticals INC. | $14.95 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.10 | 2023 | |
| Shionogi INC | $12.87 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.80 | 2023 | Quviviq |
| Redhill Biopharma INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.